Recent advances in transarterial therapy of primary and secondary liver malignancies

Sanjeeva P. Kalva, Ashraf Thabet, Stephan Wicky

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

The management of liver malignancies presents many challenges. Few patients with primary hepatocellular carcinoma or metastatic disease of the liver are eligible for surgery, which is the only curative therapeutic option. Because the hepatic tumor burden is often a determinant of eligibility for surgery and is a primary contributor to morbidity and mortality, an increasing number of innovative techniques based on the transarterial administration of liver-directed drug-eluting or radiation-emitting microspheres are being tested for use in cytoreductive and palliative therapy. The delivery of therapy via a transarterial route takes advantage of the fact that hepatic malignancies are primarily supplied by the hepatic artery. The early results of clinical trials are promising; the clinical effectiveness and safety of drug-eluting and yttrium-90-bearing microspheres have been demonstrated; however, further clinical investigation is needed to verify a benefit in survival. Transarterially administered gene therapy holds promise but is still in the early stages of investigation. For all transarterial therapies, the outcome depends heavily on meticulous patient selection, careful preparation and administration of therapy, and early and regular follow-up evaluations by using an interdisciplinary approach.

Original languageEnglish (US)
Pages (from-to)101-117
Number of pages17
JournalRadiographics
Volume28
Issue number1
DOIs
StatePublished - Jan 2008

Fingerprint

Liver
Microspheres
Neoplasms
Yttrium
Hepatic Artery
Therapeutics
Tumor Burden
Palliative Care
Pharmaceutical Preparations
Genetic Therapy
Patient Selection
Liver Diseases
Hepatocellular Carcinoma
Clinical Trials
Radiation
Morbidity
Safety
Survival
Mortality

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

Recent advances in transarterial therapy of primary and secondary liver malignancies. / Kalva, Sanjeeva P.; Thabet, Ashraf; Wicky, Stephan.

In: Radiographics, Vol. 28, No. 1, 01.2008, p. 101-117.

Research output: Contribution to journalArticle

Kalva, Sanjeeva P. ; Thabet, Ashraf ; Wicky, Stephan. / Recent advances in transarterial therapy of primary and secondary liver malignancies. In: Radiographics. 2008 ; Vol. 28, No. 1. pp. 101-117.
@article{bb0474a50ced4fedaaab0527a57f3fe8,
title = "Recent advances in transarterial therapy of primary and secondary liver malignancies",
abstract = "The management of liver malignancies presents many challenges. Few patients with primary hepatocellular carcinoma or metastatic disease of the liver are eligible for surgery, which is the only curative therapeutic option. Because the hepatic tumor burden is often a determinant of eligibility for surgery and is a primary contributor to morbidity and mortality, an increasing number of innovative techniques based on the transarterial administration of liver-directed drug-eluting or radiation-emitting microspheres are being tested for use in cytoreductive and palliative therapy. The delivery of therapy via a transarterial route takes advantage of the fact that hepatic malignancies are primarily supplied by the hepatic artery. The early results of clinical trials are promising; the clinical effectiveness and safety of drug-eluting and yttrium-90-bearing microspheres have been demonstrated; however, further clinical investigation is needed to verify a benefit in survival. Transarterially administered gene therapy holds promise but is still in the early stages of investigation. For all transarterial therapies, the outcome depends heavily on meticulous patient selection, careful preparation and administration of therapy, and early and regular follow-up evaluations by using an interdisciplinary approach.",
author = "Kalva, {Sanjeeva P.} and Ashraf Thabet and Stephan Wicky",
year = "2008",
month = "1",
doi = "10.1148/rg.281075115",
language = "English (US)",
volume = "28",
pages = "101--117",
journal = "Radiographics",
issn = "0271-5333",
publisher = "Radiological Society of North America Inc.",
number = "1",

}

TY - JOUR

T1 - Recent advances in transarterial therapy of primary and secondary liver malignancies

AU - Kalva, Sanjeeva P.

AU - Thabet, Ashraf

AU - Wicky, Stephan

PY - 2008/1

Y1 - 2008/1

N2 - The management of liver malignancies presents many challenges. Few patients with primary hepatocellular carcinoma or metastatic disease of the liver are eligible for surgery, which is the only curative therapeutic option. Because the hepatic tumor burden is often a determinant of eligibility for surgery and is a primary contributor to morbidity and mortality, an increasing number of innovative techniques based on the transarterial administration of liver-directed drug-eluting or radiation-emitting microspheres are being tested for use in cytoreductive and palliative therapy. The delivery of therapy via a transarterial route takes advantage of the fact that hepatic malignancies are primarily supplied by the hepatic artery. The early results of clinical trials are promising; the clinical effectiveness and safety of drug-eluting and yttrium-90-bearing microspheres have been demonstrated; however, further clinical investigation is needed to verify a benefit in survival. Transarterially administered gene therapy holds promise but is still in the early stages of investigation. For all transarterial therapies, the outcome depends heavily on meticulous patient selection, careful preparation and administration of therapy, and early and regular follow-up evaluations by using an interdisciplinary approach.

AB - The management of liver malignancies presents many challenges. Few patients with primary hepatocellular carcinoma or metastatic disease of the liver are eligible for surgery, which is the only curative therapeutic option. Because the hepatic tumor burden is often a determinant of eligibility for surgery and is a primary contributor to morbidity and mortality, an increasing number of innovative techniques based on the transarterial administration of liver-directed drug-eluting or radiation-emitting microspheres are being tested for use in cytoreductive and palliative therapy. The delivery of therapy via a transarterial route takes advantage of the fact that hepatic malignancies are primarily supplied by the hepatic artery. The early results of clinical trials are promising; the clinical effectiveness and safety of drug-eluting and yttrium-90-bearing microspheres have been demonstrated; however, further clinical investigation is needed to verify a benefit in survival. Transarterially administered gene therapy holds promise but is still in the early stages of investigation. For all transarterial therapies, the outcome depends heavily on meticulous patient selection, careful preparation and administration of therapy, and early and regular follow-up evaluations by using an interdisciplinary approach.

UR - http://www.scopus.com/inward/record.url?scp=38349178596&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38349178596&partnerID=8YFLogxK

U2 - 10.1148/rg.281075115

DO - 10.1148/rg.281075115

M3 - Article

C2 - 18203933

AN - SCOPUS:38349178596

VL - 28

SP - 101

EP - 117

JO - Radiographics

JF - Radiographics

SN - 0271-5333

IS - 1

ER -